Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2026, Vol. 31 ›› Issue (10): 1385-1391.doi: 10.12092/j.issn.1009-2501.2026.10.009
Lanlan JIA(
), Dandan FENG, Xiaowan WANG, Liang XU(
)
Received:2026-03-04
Revised:2026-10-13
Online:2026-10-26
Published:2026-11-11
Contact:
Liang XU
E-mail:jialanlan89@163.com;xuliang_57@sohu.com
CLC Number:
Lanlan JIA, Dandan FENG, Xiaowan WANG, Liang XU. Clinical outcomes of glucocorticoid tapering and withdrawal after remission in isolated polymyalgia rheumatica: a single-center retrospective study[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(10): 1385-1391.
| Variable | GC group (n=25) | GC+TWgroup (n=29) | GC+MTX group (n=32) | P value |
| GC withdrawal rate, n(%) | 16 (64.0%) | 15 (51.7%) | 16 (50.0%) | 0.532 |
| GC tapering duration, months, median (IQR) | 19.8 (14.8, 38.7) | 27.0 (21.0, 44.0) | 26.3 (19.9, 45.6) | 0.245 |
| Time to clinical remission, months, median (IQR) | 6.0 (3.0, 7.5) | 6.0 (3.0, 7.5) | 6.0 (3.0, 8.8) | 0.707 |
| Time from clinical remission to GC discontinuation, months, median (IQR) | 15.1 (9.4, 31.2) | 21.0 (18.0, 38.0) | 23.5 (16.0, 38.0) | 0.102 |
| Relapse after GC withdrawal, n(%) | 0 (0.0%) | 3 (20.0%) | 2 (12.5%) | 0.181 |
Table 1 GC withdrawal and outcomes in three groups of patients with isolated PMR
| Variable | GC group (n=25) | GC+TWgroup (n=29) | GC+MTX group (n=32) | P value |
| GC withdrawal rate, n(%) | 16 (64.0%) | 15 (51.7%) | 16 (50.0%) | 0.532 |
| GC tapering duration, months, median (IQR) | 19.8 (14.8, 38.7) | 27.0 (21.0, 44.0) | 26.3 (19.9, 45.6) | 0.245 |
| Time to clinical remission, months, median (IQR) | 6.0 (3.0, 7.5) | 6.0 (3.0, 7.5) | 6.0 (3.0, 8.8) | 0.707 |
| Time from clinical remission to GC discontinuation, months, median (IQR) | 15.1 (9.4, 31.2) | 21.0 (18.0, 38.0) | 23.5 (16.0, 38.0) | 0.102 |
| Relapse after GC withdrawal, n(%) | 0 (0.0%) | 3 (20.0%) | 2 (12.5%) | 0.181 |
| Variable | GC withdrawal ≤2 years (n=33) | GC withdrawal >2 years (n=14) | t/z/χ2 | P value |
| Age, years | 66.4±9.8 | 66.8±7.4 | ?0.123 | 0.902 |
| Female sex, n(%) | 25(75.8%) | 12(85.7%) | 0.582 | 0.446 |
| Symptom duration, months | 2(1,18) | 3.5(1,6) | ?0.306 | 0.760 |
| ESR, mm/hour | 58.0±22.2 | 60.5±28.8 | ?0.319 | 0.751 |
| CRP, mg/L | 30.4(14.1,57.8) | 34.6(22.8,55.8) | ?0.512 | 0.609 |
| NLR | 3.0(2.0,4.5) | 3.7(2.6,5.0) | ?1.163 | 0.245 |
| Hemoglobin, g/L | 108.5±14.4 | 110.0±15.6 | ?0.322 | 0.749 |
| Platelet count, ×109/L | 265.4±88.4 | 230.1±80.0 | 1.284 | 0.206 |
| Ferritin, ng/mL | 279.7(192.5,356.1) | 229.6(177.1,296.8) | ?1.210 | 0.226 |
| Alb, g/L | 34.6±3.9 | 34.1±3.6 | 0.475 | 0.637 |
Table 2 Comparison of baseline characteristics between the 2-year withdrawal group and the >2-year withdrawal group
| Variable | GC withdrawal ≤2 years (n=33) | GC withdrawal >2 years (n=14) | t/z/χ2 | P value |
| Age, years | 66.4±9.8 | 66.8±7.4 | ?0.123 | 0.902 |
| Female sex, n(%) | 25(75.8%) | 12(85.7%) | 0.582 | 0.446 |
| Symptom duration, months | 2(1,18) | 3.5(1,6) | ?0.306 | 0.760 |
| ESR, mm/hour | 58.0±22.2 | 60.5±28.8 | ?0.319 | 0.751 |
| CRP, mg/L | 30.4(14.1,57.8) | 34.6(22.8,55.8) | ?0.512 | 0.609 |
| NLR | 3.0(2.0,4.5) | 3.7(2.6,5.0) | ?1.163 | 0.245 |
| Hemoglobin, g/L | 108.5±14.4 | 110.0±15.6 | ?0.322 | 0.749 |
| Platelet count, ×109/L | 265.4±88.4 | 230.1±80.0 | 1.284 | 0.206 |
| Ferritin, ng/mL | 279.7(192.5,356.1) | 229.6(177.1,296.8) | ?1.210 | 0.226 |
| Alb, g/L | 34.6±3.9 | 34.1±3.6 | 0.475 | 0.637 |
| Variable | β | SE | OR | 95% CI | P value |
| ESR | ?0.031 | 0.028 | 0.970 | 0.918–1.025 | 0.271 |
| CRP | 0.014 | 0.019 | 1.014 | 0.977–1.054 | 0.452 |
| Fer | ?0.002 | 0.004 | 0.998 | 0.990–1.006 | 0.593 |
| NLR | 0.512 | 0.247 | 1.669 | 1.029–2.706 | 0.038 |
Table 3 Exploratory multivariable model for factors associated with relapse after GC withdrawal
| Variable | β | SE | OR | 95% CI | P value |
| ESR | ?0.031 | 0.028 | 0.970 | 0.918–1.025 | 0.271 |
| CRP | 0.014 | 0.019 | 1.014 | 0.977–1.054 | 0.452 |
| Fer | ?0.002 | 0.004 | 0.998 | 0.990–1.006 | 0.593 |
| NLR | 0.512 | 0.247 | 1.669 | 1.029–2.706 | 0.038 |
| 1 |
Dejaco C, Kerschbaumer A, Aletaha D, et al. Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica[J]. Ann Rheum Dis, 2024, 83 (1): 48- 57.
doi: 10.1136/ard-2022-223429 |
| 2 |
Tomelleri A, van der Geest KSM, Khurshid MA, et al. Disease stratification in GCA and PMR: state of the art and future perspectives[J]. Nat Rev Rheumatol, 2023, 19 (7): 446- 459.
doi: 10.1038/s41584-023-00976-8 |
| 3 |
Dasgupta B, Cimmino MA, Kremers HM, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative[J]. Ann Rheum Dis, 2012, 71 (4): 484- 492.
doi: 10.1136/annrheumdis-2011-200329 |
| 4 |
Harkins P, Cowley S, Burke E, et al. Modern management of isolated polymyalgia rheumatica[J]. Rheumatol Ther, 2025, 12 (6): 1017- 1041.
doi: 10.1007/s40744-025-00797-z |
| 5 |
Dejaco C, Singh YP, Perel P, et al. 2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative[J]. Arthritis Rheumatol, 2015, 67 (10): 2569- 2580.
doi: 10.1002/art.39333 |
| 6 |
Leeb BF, Bird HA. A disease activity score for polymyalgia rheumatica[J]. Ann Rheum Dis, 2004, 63 (10): 1279- 1283.
doi: 10.1136/ard.2003.011379 |
| 7 |
Leeb BF, Rintelen B, Sautner J, et al. The polymyalgia rheumatica activity score in daily use: proposal for a definition of remission[J]. Arthritis Rheum, 2007, 57 (5): 810- 815.
doi: 10.1002/art.22771 |
| 8 |
Giollo A, Rossini M, Bettili F, et al. Permanent discontinuation of glucocorticoids in polymyalgia rheumatica is uncommon but may be enhanced by amino bisphosphonates[J]. J Rheumatol, 2019, 46 (3): 318- 322.
doi: 10.3899/jrheum.180324 |
| 9 | Iorio L, Bond M, Padoan R, et al. Advances in the treatment of polymyalgia rheumatica [J]. Rheumatology (Oxford), 2025, 64(Suppl 1): i48-i54. |
| 10 | Nazarinia A, Moghimi J, Toussi J. Efficacy of methotrexate in patients with polymyalgia rheumatica[J]. Koomesh, 2012, 14 (3): 265- 270. |
| 11 |
Aoki A, Kobayashi H, Yamaguchi Y. Predictors of long-term therapy with glucocorticoid in polymyalgia rheumatica[J]. Mod Rheumatol, 2021, 31 (2): 417- 420.
doi: 10.1080/14397595.2020.1777680 |
| 12 | Muratore F, Pipitone N, Hunder GG, et al. Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis[J]. Clin Exp Rheumatol, 2013, 31 (4): S86- S92. |
| 13 |
Floris A, Piga M, Chessa E, et al. Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis[J]. Clin Rheumatol, 2022, 41 (1): 19- 31.
doi: 10.1007/s10067-021-05819-z |
| 14 | Rahimi M, Esalatmanesh K, Daneshvar S, et al. Outcomes of polymyalgia rheumatica in real-world practice: a longitudinal cohort study[J]. Rom J Intern Med, 2024, 62 (3): 286- 294. |
| 15 |
Dejaco C, Matteson EL. Polymyalgia rheumatica[J]. N Engl J Med, 2026, 394 (11): 1097- 1109.
doi: 10.1056/NEJMcp2506817 |
| 16 |
Ricordi C, Pipitone N, Marvisi C, et al. Steroid-sparing agents in polymyalgia rheumatica: how will they fit into the treatment paradigm?[J]. Expert Rev Clin Immunol, 2023, 19 (10): 1195- 1203.
doi: 10.1080/1744666X.2023.2240519 |
| 17 |
Dejaco C, Singh YP, Perel P, et al. Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica[J]. Ann Rheum Dis, 2015, 74 (10): 1808- 1817.
doi: 10.1136/annrheumdis-2015-207578 |
| 18 | Yates M, Watts RA, Swords F, et al. Glucocorticoid withdrawal in polymyalgia rheumatica: the theory versus the practice[J]. Clin Exp Rheumatol, 2017, 35 (1): 1- 2. |
| 19 |
Mangoni AA, Zinellu A. Diagnostic accuracy of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in rheumatoid arthritis: a systematic review and meta-analysis[J]. Clin Exp Med, 2024, 24 (1): 207- 220.
doi: 10.1007/s10238-024-01478-x |
| 20 |
Carrión-Barberà I, Lood C, Stultz RD, et al. Diagnostic and prognostic utility of complete blood count-derived ratios in giant cell arteritis: a retrospective fast-track clinic cohort study[J]. Rheumatol Int, 2025, 45 (12): 2761- 2769.
doi: 10.1007/s00296-025-06022-y |
| 21 |
Yu R, Zhang L, Zhang J, et al. The diagnostic and prognostic role of novel biomarkers in anti-neutrophil cytoplasmic antibody-associated vasculitis[J]. Front Immunol, 2025, 16, 1588287.
doi: 10.3389/fimmu.2025.1588287 |
| 22 |
Koster MJ, Warrington KJ. Giant cell arteritis: pathogenic mechanisms and new potential therapeutic targets[J]. BMC Rheumatol, 2017, 1 (1): 2.
doi: 10.1186/s41927-017-0004-5 |
| 23 |
Yu R, Miao M, Li S, et al. The clinical characteristics and significance of novel inflammatory biomarkers in patients with polymyalgia rheumatica: a single-center study from China[J]. Cytokine, 2025, 192, 156953.
doi: 10.1016/j.cyto.2025.156953 |
| 24 |
Jung JY, Lee E, Suh CH, et al. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are associated with disease activity in polymyalgia rheumatica[J]. J Clin Lab Anal, 2019, 33 (9): e23000.
doi: 10.1002/jcla.23000 |
| [1] | Shuangmiao JIANG, Huaijun ZHU, Danying LI. Clinical research advances in the treatment of immune thrombocytopenia with hetrombopag in combination therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(3): 382-391. |
| [2] | WANG Xuebin, GAO Lihong, ZHANG Lingpeng, YANG Yunyun, LIU Hongxia, WANG Zhuo, SUN Huajun. Study on the intervention and evaluation for the abnormal results of tacrolimus therapeutic drug monitoring [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(12): 1322-1328. |
| [3] | LIU Xin, LENG Yufang, ZHANG Xuehong, ZHANG Lili, ZHANG Mengjie, QU Shanshan, XIE Jianqin, WANG Yiqing. Application of nalbuphine in ultrasound-guided transvaginal oocyte retrieval and its effect on embryo quality and pregnancy outcome [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1042-1047. |
| [4] | LI Jing, Ma Lijuan, YUAN Yuan, WANG Jie, YU Changzhi, ZHAO Jun. Relationship between gene polymorphism of inhaled glucocorticosteroids budesonide and efficacy in asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1250-1258. |
| [5] | ZHAO Qian, YANG Guang, CAO Lihua, YU Chenbao. CNR1 genetic variation influences the clinical outcomes of early stage type 2 diabetes mellitus treated with liraglutide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 182-188. |
| [6] | YU Chenchen, LIU Shuqun, LIU Jianlong, CAO Hong, LIU Xuejiao, CAI Xixi. Effects of curcumin on injury in hippocampal neurons and expression of blood corticosterone and SGK1 in hippocampal during global cerebral ischemia-reperfusion injury in hypertensive rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 737-743. |
| [7] | ZHANG Ling, XU Weihai, HUANG Qiongxiao, FU Xiaohua, ZHANG Lin, LI Shishi, ZHU Jing, WU Ruifang, SHU Jing. Efficiency of GnRH agonist trigger on embryo cultural outcomes in IVF subjects with diminished ovarian reserve [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 799-804. |
| [8] | ZHANG Danyang, DONG Xiaomin, ZHOU Xiaohuan, ZHANG Yue, ZHANG Juan, ZHOU Hebin. Gene microarray Analysis of Glucocorticoid resistance-related genes in Acute Lymphoblastic Leukemia based on GEO [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 272-277. |
| [9] | WANG Xiaqin, HE Fei, WANG Tong, HU Zhangle. Admission Neutrophil-to-lymphocyte ratio predicts coronary lesion complexity and clinical risk in patients with unstable angina pectoris [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 296-300. |
| [10] | XUE Hua, LU Lili, XIANG Hui, QIAN Zhenhua. Curative efficacy of ulinastatin combined with hydrocortisone in treatment of severe sepsis secondary shock and effects on serum factor levels [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 313-317. |
| [11] | HE Xiaobin, LIN Xiaohua, LIU Shunli, OU Huanjiao. Evaluation on drug use of systemic glucocorticoid affected by the level of eosinophils in peripheral blood of the patients with acute exacerbation of chronic obstructive pulmonary disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 89-93. |
| [12] | WANG Haixia, LIU Xingan, HOU Jiyuan, GONG Zhe, SHAN Guoyong. Influence of genetic variation of KDR on clinical outcomes of advanced NSCLC treated by first line bevacizumab regimens [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 802-808. |
| [13] | LU Xiaohong,WANG Peiguang. Progress in the treatment of dermatomyositis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 836-840. |
| [14] | HU Weihua, YAN Yongxu, RUAN Jian, HOU Wenwen. Effects of subclinical hypothyroidism on the outcome of in vitro fertilization and embryo transfer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(5): 552-556. |
| [15] | ZHANG Jun, XIE Yanyun, LI Zhi, TAO Lijian. Effects of splicing factor SRp40 on the expression of GRα/β mRNA and on glucocorticoid therapy for nephrotic syndrome [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(5): 589-593. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||